PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 11: Articles 5001-5500 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Oral contraceptives and cyproterone acetate in female acne treatment.
  2. Oral contraceptives and endometrial and ovarian carcinomas. ["Pille" und Endometrium- sowie Ovarialkarzinome.]
  3. Oral contraceptives and risk of venous thromboembolism: impact of duration of use [letter]
  4. Oral contraceptives and sickle cell disease.
  5. Oral contraceptives and the risk of hereditary ovarian cancer.
  6. Oral contraceptives and the risk of subarachnoid hemorrhage: a meta-analysis.
  7. Oral contraceptives and thrombosis.
  8. Oral contraceptives and thrombosis.
  9. Oral contraceptives and thrombosis: an overview of study methods and recent results.
  10. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
  11. Oral contraceptives and venous thromboembolism: a case-control study.
  12. Oral contraceptives and venous thrombosis: end of the debate?
  13. Oral contraceptives are cost-effective when used as emergency method.
  14. Oral contraceptives cut inherited cancer risk.
  15. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females.
  16. Our experiences with an oral hormonal contraceptive containing gestodene. [Gestoden tartalmu hormonalis fogamzasgatloval szerzett tapasztalataink.]
  17. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant.
  18. Over-the-counter emergency contraception: a feasible option.
  19. Overview -- Meeting contraceptive needs worldwide: the role of monthly combined contraceptives.
  20. Overview of adolescent health services in Jamaica --perspective of the National Family Planning Board.
  21. Pain control in voluntary surgical contraception.
  22. Pakistan Contraceptive Prevalence Survey 1994-95: final report.
  23. In Pakistan, contraceptive prevalence is increasing, but fertility remains high.
  24. Parents' viewpoint on reproductive health and contraceptive practice among sexually active adolescents in the Port Harcourt local government area of Rivers State, Nigeria.
  25. Partnership for family planning services [letter]
  26. Paying for family planning.
  27. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.
  28. Perimenstrual dermatitis secondary to a copper-containing intrauterine contraceptive device.
  29. Persona: contraception naturally. [Persona: ehkaisya luonnollisesti.]
  30. Pharmacist survey of contraceptive availability, knowledge and practices, Romania, 1998.
  31. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
  32. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids.
  33. Pill cycle disturbances during simultaneous use of itraconazole and oral contraceptives. [Verstoring van de pilcyclus tijdens het gelijktijdig gebruik van itraconazol en orale anticonceptiva.]
  34. Pill power: oral contraceptives hold top spot in family planning arsenal.
  35. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary.
  36. Planned Parenthood of Wisconsin v. Doyle.
  37. Pocket guide to managing contraceptive supplies.
  38. Policies on family planning and the aged population. [Políticas de planeamento familiar e populaçào envelhecida.]
  39. Pope calls for research into natural family planning.
  40. Post-abortion contraception. [Anticoncepcion postaborto.]
  41. Postcoital contraception (letter) [Anticoncepcion poscoital.]
  42. Postpartum contraceptive use in Bangladesh: understanding users' perspectives.
  43. Postpartum family planning services in the Philippines: an assessment of current service provision and future program requirements.
  44. Potential barriers to the removal of Norplant among family planning clinic patients.
  45. Poverty, sexual and reproductive health: recommendations for family planning associations.
  46. Predicting adolescents' initiation of intercourse and contraceptive use.
  47. Predicting teenage girls' sexual activity and contraception use: an application of matching law.
  48. Pregnancies and terminations after 1995 warning about third-generation oral contraceptives [letter]
  49. Preliminary analysis of a multicenter clinical trial using Multiload Cu 375SL for emergency contraception.
  50. Preliminary studies with recombinant chorionic gonadotropin beta-subunit produced in Escherichia coli for use as an antigen in a birth control vaccine.
  51. Prepare family planning patients for successful pill-taking.
  52. Present stage of knowledge of reproductive biology concerning natural family planning.
  53. President Jiang Zemin on family planning and environmental protection.
  54. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
  55. Prevalence and determinants of current contraceptive method use in a palm oil company in Cameroon.
  56. Preventing teen pregnancy with emergency contraception: an opportunity we should not be missing [editorial]
  57. Prevention of thromboembolic complications associated with oral contraceptive use: recommendation for changing the protocol of first prescription. [Oralis fogamzasgatlas thromboembolias szovodmenyeinek megelozese: modszertani javaslat.]
  58. Prior oral contraceptive use is associated with higher blood pressure in older women.
  59. A profile of family planning audit in England 1994-1997.
  60. A profile of the adolescent male family planning client.
  61. Project: Strengthening of the Post-Partum and Post-Abortion Family Planning Program in the Hospital Escuela, Infant Maternal Wing, Secretary of Health, Honduras. Final Report.
  62. Project: Strengthening of the Postpartum and Postabortion Program in Family Planning in the Hospital Escuela. Final report.
  63. Promoting emergency contraception.
  64. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata.
  65. Prospective study of the effectiveness of a new sympto-thermal method of natural family planning. [Etude prospective d'efficacite d'une methode sympto-thermique recente de planning familial naturel.]
  66. Prostate specific antigen production by breast tumors after induction with oral contraceptives.
  67. Providing effective reproductive health care and prescribing contraceptives for adolescents.
  68. Providing emergency contraception in Ecuador: assessing the impacts of training and practice. [Prestación de servicios de anticoncepción de emergencia en Ecuador: evaluación de los impactos de la capacitación y la práctica.]
  69. Psychological aspects of contraception. [Aspectos psicológicos de la anticoncepción.]
  70. Purposive program placement and the estimation of family planning program effects in Tanzania.
  71. Quality and costs of family planning as elicited by an adolescent mystery client trial in Nigeria.
  72. Quality of care and family planning utilization in Ministry of Health and Population clinics. Draft report.
  73. Quality of care in family planning services: an assessment of change in Tanzania 1995/6 to 1996/7.
  74. Quality of family planning services shows marked improvement.
  75. A quarter century of contraception: remarkable advances, increasing success.
  76. Quinine as unofficial contraceptive -- concerns about safety and efficacy [editorial]
  77. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception.
  78. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
  79. Rationale for prescribing oral contraceptives. [Rationale fur die Verordnung oraler Kontrazeptiva.]
  80. Reaching women: unmet need for family planning in Uttar Pradesh, India.
  81. Recent advances in contraception.
  82. Recent medical news. Oral contraceptives and health.
  83. Recommendations for clinical practice: actinomyces like organisms and intrauterine contraceptives.
  84. Recommendations for clinical practice: actinomyces like organisms and intrauterine contraceptives.
  85. Recommendations for clinical practice: emergency contraception. Prepared on behalf of the Faculty of Family Planning and Reproductive Health Care of the RCOG.
  86. Recommendations for oral contraception. 20th Professional Meeting of the Zurich Discussion Group, April 1998. [Empfehlungen zur oralen Kontrazeption. 20 Arbeitstreffen des Zurcher Gesprachskreises, April 1998.]
  87. Recommendations on the safety of oral contraceptives are too important for the regulating agencies alone.
  88. Recruitment underway for oral contraceptive trial.
  89. Recurrent haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive [letter]
  90. Reducing pregnancy and induced abortion rates in China: family planning with husband participation.
  91. Reducing teenage and unintended pregnancies through client-centered and family-focused school-based family planning programs.
  92. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
  93. Regulations on family planning management of the floating population.
  94. Reorientation of national family planning programmes toward a broader reproductive health, including family planning and sexual health, approach in East and South-East Asia.
  95. The replacement of abortion by contraception in three Central Asian republics. Executive summary.
  96. Report says Catholic hospital mergers threaten family planning, abortion services.
  97. Reproduction, risk and reality: family planning and reproductive health in northern Vietnam.
  98. Reproductive goals and family planning attitudes in Pakistan: a couple-level analysis.
  99. Reproductive health -- the role of the National Family Planning Board.
  100. Reproductive health and family planning in underserved communities in the Southern Nations, Nationalities and People's Regional State of Ethiopia: findings from a baseline survey, 1997.
  101. Reproductive life cycles and patterns of contraceptive use: an analysis of the 1992 and 1995 Egypt Demographic and Health Surveys.
  102. Reproductive mishaps and Western contraception: an African challenge to fertility theory.
  103. Reproductive rights in contraceptive practices.
  104. Reproductive tract infections in primary healthcare, family planning, and dermatovenereology clinics: evaluation of syndromic management in Morocco.
  105. Research efforts focus on male contraception.
  106. Research report. Informed Choice of Contraception after an Obstetric Event. INOPAL III final report. Volume II: Annex. Results tables. [Informe de investigacion: Consentimiento Informado entre Aceptantes de Metodos Anticonceptivos despues de un Evento Obstetrico. Anexo: Cuadros de resultados.]
  107. Research report: Informed Choice of Contraception after an Obstetric Event. INOPAL III final report. [Informe de investigacion: Consentimiento Informado entre Aceptantes de Metodos Anticonceptivos despues de un Evento Obstetrico.]
  108. Resistance to activated protein C in women using oral contraceptives.
  109. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
  110. Retrospective clinical trial of contraceptive effectiveness of the electronic fertility indicator Ladycomp / Babycomp.
  111. A review of bacteriological culture of removed intrauterine contraceptive devices.
  112. Reviewing print materials for oral contraceptives: directions for the future.
  113. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study.
  114. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.
  115. Sexually transmitted diseases are common in women attending Jamaican family planning clinics and appropriate detection tools are lacking.
  116. Sexually transmitted diseases, cervical cytology and contraception in immigrants and refugees from the former Yugoslavia.
  117. Should condom use be promoted for contraception to prevent transmission of sexual transmitted diseases and AIDS?
  118. Should emergency contraceptive pills be available without prescription in Europe?
  119. Side effects and discontinuation rates of intrauterine contraceptive device use in the Jilin province of China.
  120. Situation analysis of family planning services identifies program gaps.
  121. Social and economic consequences of family planning use in the case of southern Philippines.
  122. Socio-demographic characteristics of family planning clients and their possible influence on contraception in Malawi.
  123. Socioeconomic status and use of family planning among Ghanaian government workers.
  124. SOMARC addresses contraceptive needs of post abortion clients in Turkey.
  125. Sonographic characteristics of various types of intrauterine contraceptive devices.
  126. Speaking graphically. Percentage of U.S. women in managed care plans who reported access or service problems regarding contraceptive care.
  127. Spinal bone density in women using depot medroxyprogesterone contraception.
  128. A statistical portrait of adolescent sex, contraception, and childbearing.
  129. Status of women: fertility and contraception in peninsular states of India.
  130. Strategies for improving the quality and performance of clinical contraceptive services.
  131. Strengthening family planning and reproductive health services through gender training, INOPAL III, Population Council Subcontract No. CI95.54A. Final progress report: June 1995 - August 1998.
  132. Strengthening the utilization of family planning operations research: findings from case studies in Africa.
  133. Stroke and steroid hormonal contraception.
  134. Stroke and use of low-dose oral contraceptives in young women. A pooled analysis of two US studies.
  135. Structure of family planning in Samoa.
  136. A study of the interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity and glucose tolerance in normotensive women.
  137. A study of the operations of the contraceptive logistics system of the population welfare programme.
  138. A study on "background characteristics of women sterilized" at Comprehensive Family Planning Clinic, Family Planning Association of India, Bhopal, Madhya Pradesh.
  139. Subdermal implantable contraceptives versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
  140. The supermarket for women's reproductive health: the burden of genital infections in a family planning clinic in Nairobi, Kenya.
  141. Systematic provision of family planning and reproductive health services in Guatemala. [Oferta sistematica de servicios de planificacion familiar y salud reproductiva en Guatemala.]
  142. T-cell-rich B-cell lymphoma and Epstein-Barr virus infection of the uterus in a postmenopausal patient with an intrauterine contraceptive device in place for over 20 years.
  143. Teenagers' views on seeking contraceptive advice [letter]
  144. Test your knowledge: contraceptives. [Testez vos connaissances. Contraceptifs.]
  145. Thailand National Contraceptive Prevalence Survey 1996. Executive summary.
  146. Thailand: National Family Planning Programme.
  147. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism.
  148. Thirty years and beyond: National Family Planning Board's travelling exhibition.
  149. Thromboembolic stroke in young women. A European case-control study on oral contraceptives.
  150. Thrombotic diseases in young women and the influence of oral contraceptives.
  151. Time for emergency contraception with levonorgestrel alone.
  152. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
  153. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
  154. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
  155. Together for a happy family: a men's participation in family planning campaign in Jordan. Concept paper.
  156. Towards a change in status of emergency contraception [editorial]
  157. Training of trainers manual for departmental training teams in reproductive health and family planning, Ministerio de Salud, El Salvador. [Manual para la capacitacion a capacitadores, equipos departamentales de capacitacion en salud reproductiva y planificacion familiar. Ministerio de Salud de El Salvador.]
  158. Trends and correlates of contraceptive use in Kenya: 1977-1993.
  159. Trends in contraceptive use in the United States: 1982-1995.
  160. Trends in sexual and contraceptive behaviour.
  161. A trendsetter in China's rural family planning programme.
  162. Trust: an approach to women's empowerment. Lessons learned from an evaluation on empowerment and family planning with women's organizations.
  163. Twelve brands of emergency contraceptive pills in the United States.
  164. Twelve years of injectable contraceptive use in a general practice.
  165. Twenty-four month comparison of apolipoproteins A-1, A-II, and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom.
  166. The two-child family: the Egyptian model of family planning.
  167. Two-year treatment with oral contraceptives in hyperprolactinemic patients.
  168. Underused IUDs offer safe, effective contraception [letter]
  169. Uniqueness of oral contraceptive progestins.
  170. Unmet need for family planning.
  171. Unmet need for family planning: reflecting women's perceptions.
  172. Unrealized quality and missed opportunities in family planning services.
  173. Uptake of contraception during postpartum amenorrhoea: understandings and preferences of poor, urban women in Bangladesh.
  174. Uptake of family planning services among an ethnically mixed population in a general practice setting.
  175. Urban women educate their community on HIV / STDs, family planning and reproductive health.
  176. US contraceptive mandate dropped.
  177. US House of Representatives divided over family planning.
  178. Use of intrauterine contraceptive devices in nulliparous women: personal experience over a 12-year period.
  179. The use of oral contraception by adolescents for contraception, menstrual cycle problems or acne.
  180. Use of oral contraceptives and risk of breast cancer in young women.
  181. The use of testosterone as a male contraceptive.
  182. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study.
  183. Users of injectable contraception in Bangladesh.
  184. Using COPE to improve quality of care: the experience of the Family Planning Association of Kenya.
  185. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives.
  186. Using mass media to improve contraceptive behavior: the Burkina Faso family planning expansion project, 1992-1995.
  187. Using pharmacies in Washington State to expand access to emergency contraception.
  188. Using situation analysis to assess women's perceptions of quality of maternal-child health and family planning services.
  189. Utilisation of MCH and family planning services by a scheduled caste community in Mysore district.
  190. Vaginal bleeding patterns in users of Perlutal, a once-a-month injectable contraceptive consisting of 10 mg estradiol enanthate combined with 150 mg dihydroxyprogesterone acetophenide. A trial of 5462 woman-months.
  191. Vaginal contraceptive rings: option for the new millennium.
  192. The value of family planning programs in developing countries.
  193. Vasectomy or male sterilization -- still the most frequent solution to contraceptive problems. [Vasektomia eli miehen sterilisaatio: yha useammin ratkaisu ehkaisyongelmaan.]
  194. Venous thromboembolism and the pill. Incomplete compensation following the ban on third generation oral contraceptives.
  195. Venous thromboembolism and the pill. The WHO technical report on cardiovascular disease and steroid hormone contraception: state-of-the-art.
  196. Views of Cameroonian sex workers on a woman-controlled method of contraception and disease protection.
  197. Village networks and patterns of contraceptive choice.
  198. Village-based workers increase women's access to family planning.
  199. Warning about contraceptive device given.
  200. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements.
  201. Weight variation in users of the once-a-month injectable contraceptive Cyclofem.
  202. What are family planning clinics for? [letter]
  203. What are family planning clinics for? [letter]
  204. What are family planning clinics for? [letter]
  205. What are family planning clinics for? [letter]
  206. What are family planning clinics for? [letter]
  207. What are family planning clinics for? [letter]
  208. What methods should be included in a contraceptive coverage insurance mandate?
  209. When is breast feeding contraceptive? [Quand l'allaitement maternel est-il contraceptif?]
  210. When plans opt out: family planning access in Medicaid managed care.
  211. When the morning after is Sunday: pharmacist prescribing of emergency contraceptive pills.
  212. When there is no suitable contraceptive method. [Kun sopivaa ehkaisymenetelmaa ei loydy.]
  213. Which contraceptive methods are recommended for young women with type 1 diabetes mellitus? A survey among practitioners in Germany. [Welches Kontrazeptivum empfehlen Sie einer Jugendlichen mit Typ I Diabetes? Eine Umfrage unter Gynakologen / -Innen.]
  214. Who has told you to do this thing?: contraception as subversion in Rhodesia 1970-1980.
  215. Women and contraception.
  216. Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy.
  217. Women's choice between indigenous and western contraception in urban Mozambique.
  218. Women's efforts to prevent pregnancy: consistency of oral contraceptive use.
  219. Women's interest in natural family planning.
  220. Women's preferences for vaginal antimicrobial contraceptives I. Methodology.
  221. Women's preferences for vaginal antimicrobial contraceptives II. Preferred characteristics according to women's age and socioeconomic status.
  222. Women's preferences for vaginal antimicrobial contraceptives III. Choice of a formulation, applicator, and packaging.
  223. Women's preferences for vaginal antimicrobial contraceptives IV. Attributes of a formulation that would protect from STD / AIDS.
  224. Workshop on emergency contraception as an element in the care of rape victims for staff of the Attorney General offices of Mexican states. INOPAL III final report.
  225. Workshop on the consolidation strategies of reproductive health programs. Family Planning section. Report. [Atelier sur les strategies de consolidation des programmes de sante reproductive. Volet planification familiale. Rapport.]
  226. Young women's attitudes toward injectable and implantable contraceptives.
  227. Youth Activists Organisation's youth sexual and reproductive health and football camps. Report on Chongwe and Kafue. Increasing male participation in sexual reproductive health and family planning.
  228. Youth centres in Ghana. Assessment of the Planned Parenthood Association of Ghana programme.
  229. Sexual activity and contraceptive knowledge and use among in-school adolescents in Nigeria.
  230. Avoiding unintended pregnancy in Peru: does the quality of family planning services matter?
  231. Husband-wife communication about family planning and contraceptive use in Kenya.
  232. The relationship of abortion to trends in contraception and fertility in Brazil, Colombia and Mexico.
  233. Action of intrauterine contraceptive devices. Reply [letter]
  234. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception.
  235. Analysis of contraceptive discontinuation in six developing countries from durations of use at survey.
  236. Association of contraceptives and HIV-1 infection in Thai female commercial sex workers.
  237. Attitudes of general practitioners in Northern Ireland toward abortion and family planning.
  238. Balanced view of risks of oral contraceptives.

     

  239. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months.
  240. Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years.
  241. The cardiovascular safety of triphasic contraceptive steroids.
  242. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls.
  243. Combined oral contraceptives and liver disease.
  244. Community-level determinants of contraceptive use in the Philippines: a structural analysis.
  245. Comparison between testosterone oenanthate-induced azoospermia and oligozoospermia in a male contraceptive study. IV. Suppression of endogenous testicular and adrenal androgens.
  246. Consistency of condom use among users of injectable contraceptives.
  247. Contraceptive choice and reproductive morbidity in Istanbul.
  248. Contraceptive continuation and its determinants in Benin.
  249. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres (NET-90): phase III clinical study.
  250. Contraceptive knowledge and attitudes of Austrian adolescents after mass media reports linking third-generation oral contraceptives with an increased risk of venous thromboembolism.
  251. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use.
  252. Contraceptive use among adolescent mothers at 6 months postpartum.
  253. Differences in macronutrient selections in users and nonusers of an oral contraceptive.
  254. Do family planning programs affect fertility preferences? A literature review.
  255. The effects of oral contraceptives on delayed onset muscle soreness following exercise.
  256. Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity.
  257. Emergency contraception: a national survey of adolescent health experts.
  258. Family planning in the Jewish population of Israel: correlates of withdrawal use.
  259. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
  260. A hierarchical model of contraceptive use in urban and rural Bangladesh.
  261. Injectable contraceptive discontinuation and subsequent unintended pregnancy among low-income women.
  262. Intrauterine contraception in adolescent women. The GyneFix intrauterine implant.
  263. Knowledge and use of hormonal emergency contraception in Finland.
  264. The levonorgestrel-releasing intrauterine device: a wider role than contraception.
  265. Long-acting hormonal contraception.
  266. Mechanism of action of intrauterine contraceptive devices and its relation to informed consent.
  267. Minimizing the problem of poor compliance in adolescents. Clinical experience with a modern low-dose gestodene-containing oral contraceptive.
  268. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
  269. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
  270. Modulation of uterine artery resistance to blood flow by the oral contraceptive pill.
  271. Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate.
  272. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms.
  273. The Nova-T 200 intrauterine contraceptive device: a 12 year study.
  274. Oral contraception and the recognition of endometritis.
  275. Oral contraception and vaginal candida colonization. [Einnahme oraler Kontrazeptiva und vaginale Kandidabesiedlung.]
  276. Oral contraceptive use among female elite athletes and age-matched controls and its relation to low back pain.
  277. Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect of birth year.
  278. Oral contraceptives and ovulatory causes of delayed fertility.
  279. Ovarian volume in gynecologically healthy women using no contraception, or using IUD or oral contraception.
  280. Prevalence of chlamydial infection in females attending antenatal and family planning clinics in Karachi Pakistan.
  281. Public knowledge and perceptions about unplanned pregnancy and contraception in three countries.
  282. Re-evaluation of oral contraceptive classifications.
  283. Reappearance of the intrauterine device: "a user-friendly" contraceptive.
  284. A reassessment of efficacy of the Yuzpe regimen of emergency contraception.
  285. The reliability of reporting of contraceptive behavior in DHS calendar data: evidence from Morocco.
  286. Risk factors for sexually transmitted diseases among women attending family planning clinics in Dar-es-Salaam, Tanzania.
  287. Sexually transmitted diseases and oral contraceptive use during adolescence.
  288. A study on the effects of Norplant implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women.
  289. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.
  290. Third-generation oral contraceptives and thromboembolism risk.
  291. The use of behavioural methods of contraception in women seeking abortion.
  292. Communicating family planning in reproductive health: key messages for communicators.
  293. Contraceptive choices: supporting effective use of methods.
  294. Women's perceptions and experience with the progesterone vaginal ring for contraception during breastfeeding.
  295. Is the diaphragm a suitable method of contraception for low-income women: a user perspectives study, Madras, India.
  296. Women's views and experiences of hormonal contraceptives: what we know and what we need to find out.
  297. South African women's experiences of contraception and contraceptive services.
  298. Beyond acceptability: users' perspectives on contraception.
  299. New data on oral contraceptive pills and the risk of heart attack. Press release.
  300. New data on sexual behaviors of teenage males. Sexual activity declines, contraceptive use increases from 1988 to 1995.
  301. The diaphragm as a contraceptive method in the experience of users in the public health services. [O diafragma como método contraceptivo: a experiência de usuárias de serviços públicos de saúde.]
  302. An assessment of community-based family planning programmes in Kenya.
  303. An assessment of community-based family planning programmes in Kenya.
  304. Comprehensive reproductive health and family planning training curriculum. Module 2: Infection prevention.
  305. Comprehensive reproductive health and family planning training curriculum. Module 1: Introduction to family planning and the health of women and children and an overview of family planning methods.
  306. Emergency contraception. Fact sheet.
  307. Contraception in the 90s. Contraceptive use.
  308. Integrating reproductive health into NGO programs. Volume 1: Family planning. 2nd ed.
  309. The essentials of contraceptive technology.
  310. Family planning programmes for the next century.
  311. Family planning quality and contraceptive method choice.
  312. From Norplant to the contraceptive vaccine.
  313. Maternal health care and contraceptive acceptance in Orissa: evidence from a baseline survey.
  314. Contraceptive morbidity: Is it an alarming issue in India?
  315. Family planning practice: a message from indigenous world.
  316. Quality of family planning services in India: the users' perspective.
  317. Is son preference constraining contraceptive use in India?
  318. Emergency contraception.
  319. A framework for the analysis of the impact of family planning on women's work and income.
  320. Mexico. Birthplace of the birth control pill still a hemispheric pacesetter. [México. Cuna de la píldora anticonceptiva y líder en el hemisferio.]
  321. Reassessing risk assessment: limits to predicting reproductive tract infection in new contraceptive users.
  322. A tool for monitoring the performance of family planning programs in the public and private sectors: an application in Nigeria.
  323. Intended contraceptive use among women without an unmet need.
  324. Knowledge, approval and communication about family planning as correlates of desired fertility among spouses in Pakistan.
  325. Can the Bangladeshi family planning program meet rising needs without raising costs?
  326. Spouses' views of contraception in the Philippines.
  327. Knowledge and attitudes about emergency contraception among health workers in Ho Chi Minh City, Vietnam.
  328. Preferences for contraceptive attributes: voices of women in Ciudad Juarez, Mexico.
  329. 10 years of contraceptive social marketing in Pakistan: an assessment of management, outputs, effects, costs and cost-efficiency 1987-1996.
  330. 1996 contraceptive social marketing statistics.
  331. The 1996 election: what it will mean to international family planning.
  332. Abortion and contraceptive practices in Eastern Europe.
  333. Abortion and emergency contraception: Chinese experience.
  334. Abortion in the framework of family planning in Estonia.
  335. Acceptability of contraceptives in young couples.
  336. Acceptance and acceptability of modern family planning in Eastern Europe.
  337. Access to contraception: a global survey.
  338. Access to family planning services: relationship with unintended pregnancies and prenatal outcomes [editorial]
  339. Achieving sustainability of health and family planning services.
  340. ACOG practice patterns. Emergency oral contraception. Number 2, October 1996.
  341. ACOG practice patterns. Emergency oral contraception. Number 3, December 1996 (Replaces No. 2, October 1996)
  342. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice [letter]
  343. Action of intrauterine contraceptive devices [letter]
  344. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study.
  345. Acute urinary retention secondary to urethral inflammation from a vaginal contraceptive suppository in a 17-year-old boy.
  346. Addressability of contraception in adolescents. [Adresabilitatea pentru contraceptie la adolescente.]
  347. Addressing common dilemmas in contraception.
  348. Adolescence -- sexuality, contraception, natural family planning. [Adolescenta -- sexualitate, contraceptie, contragestie.]
  349. Adolescence and contraception. [Adolescencia y contracepcion.]
  350. Adolescents' access to reproductive health and family planning services in Dakar (Senegal)
  351. Advantages and disadvantages of different contraceptive methods for adolescents. [Avantaje si dezavantaje ale diferitelor metode contraceptive la adolescenti.]
  352. Adverse outcomes of planned and unplanned pregnancies among users of natural family planning: a prospective study.
  353. An African response to the challenge of integrating STD / HIV-AIDS services into family planning programs.
  354. After sharp gains in the 1980s, pace of effort devoted to family planning programs slackens in the 1990s.
  355. Alarming increase in the number of abortions. Does fear of thrombosis limit the use of oral contraceptives? [Oroande okning av antalet aborter. Radsla for blodpropp minskade p-pilleranvandningen?]
  356. Analysis of the registration status of residents in survey sample areas: 1992 National Fertility and Family Planning Survey.
  357. Annotation: emergency contraception -- parsimony and prevention in the medicine cabinet.
  358. Anti-STD vaginal contraceptive sponges.
  359. Antiandrogenic and ovulatory benefits of oral contraception.
  360. APC resistance, oral contraceptives and thrombosis. Screening is justified for diagnosing high-risk cases. [APC-resistens, p-piller och trombos. Screening motiverad for att finna hogriskfall.]
  361. Assessing family planning service-delivery skills in Kenya.
  362. Assessing the policy impact of operations research on the Bangladesh Health and Family Planning Programme.
  363. Assessing the post-training family planning service delivery skills of clinical providers in Kenya. FCA-26.
  364. An assessment of clinic-based family planning services in Kenya: results from the 1995 situation analysis study.
  365. An assessment of recent levels and trends in long-term contraceptive method use in Indonesia.
  366. An assessment of the contraceptive method mix in Myanmar.
  367. Assessment of the quality of family planning services in selected service delivery points in the Philippines.
  368. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa Heart Study.
  369. Attitudes of female college students toward over-the-counter availability of oral contraceptives.
  370. Attitudes toward family planning and reasons for nonuse among women with unmet need for family planning in Nepal.
  371. Attributes of contraceptive methods.
  372. Attributes of contraceptive technology: women's preferences in seven countries.
  373. Automatic audit -- would a system of standardised national data collection about family planning services be useful or even possible?
  374. Awareness of emergency contraception is limited among American adults.
  375. Balancing risks and benefits of oral contraception [editorial]
  376. Bangladesh Family Planning Programme: lessons learned and directions for the future.
  377. Barriers to contraceptive use among Pakistani couples.
  378. Basic principles in family planning service delivery: informed choice.
  379. The behavior of Italian family physicians regarding the health problems of women and, in particular, family planning (both contraception and NFP)
  380. Beliefs related to the use of oral contraceptives by African American women, ages 18-35.
  381. The benefits and barriers associated with a national natural family planning service: the New Zealand experience.
  382. Benign gallbladder disease: newer data suggest little or no excess risk with oral contraceptive use.
  383. Beyond acceptability: reorienting research on contraceptive choice.
  384. Beyond access: addressing the unmet need for family planning.
  385. Bias in studies of venous thromboembolism in relation to the use of new formulations of oral contraceptives [letter]
  386. Biochemical aspects of hormonal contraception: effects on bone metabolism.
  387. Biodegradable norethindrone (NET:cholesterol) contraceptive implants: phase II-A: a clinical study in women.
  388. Birth control as an international program.
  389. Birth control versus AIDS prevention: a hierarchical model of condom use among young people.
  390. Birth control: some experiences from Denmark.
  391. Birth-based approach to family planning: an empirical justification.
  392. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994.
  393. Bolivia: views of family planning.
  394. Breaking the silence on emergency contraception.
  395. Breast feeding as family planning in a global perspective. [Amming som familieplanlegging v globalt perspektiv.]
  396. Bringing men and women closer in family planning clinics. [Acercando a hombres y mujeres en las clinicas de planificacion familiar.]
  397. Building on the past, looking to the future: strategies for natural family planning and reproductive health awareness. Final report of the Natural Family Planning and Fertility Awareness Division. Accomplishments, results and recommendations under USAID cooperative agreement DPE-3040-A-00-5064-00, July 1, 1991 - June 30, 1997, Initiatives in Natural Family Planning and Breastfeeding.
  398. The buzz outside the clinics: conversations and contraception in Nyanza province, Kenya.
  399. Campaign launched to tell physicians, public about emergency contraception.
  400. A case control study of breast cancer risk and exposure to injectable progestogen contraceptives. Methods and patterns of use among controls.
  401. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women.
  402. Cervical cancer screening in women attending a family planning clinic in Nairobi, Kenya.
  403. Changes in family planning. [Cambios en planificacion familiar.]
  404. Changes in the menstrual bleeding of users of a subdermal contraceptive implant of nomegestrol acetate (Uniplant) do not influence sexual frequency, sexual desire, or sexual enjoyment.
  405. Changes in the use of contraceptive methods in England and Wales over two decades: Margaret Bone's surveys and the National Survey of Sexual Attitudes and Lifestyles.
  406. China intensifies IEC programme for family planning.
  407. Chlamydia infection in UK family planning clinics.
  408. Chlamydia testing within family planning services: an audit of compliance with policies.
  409. Chronic pelvic pain: oral contraceptives and non-steroidal anti-inflammatory compounds.
  410. Client-provider interactions (CPI) in family planning services: guidance from research and program experience.
  411. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
  412. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
  413. Clinical guidelines on contraception and diabetes.

     

  414. Clinical overview of hormonal contraception with special emphasis on long-term effects.
  415. A clinical study of the lactational amenorrhea method for family planning in Egypt.
  416. Clinton renews family planning fight.
  417. Combination oral contraceptives.
  418. Combined oral contraception and the risk of venous thromboembolism.
  419. Combined oral contraceptives and gonadotropin releasing hormone agonistic analogs in polycystic ovary syndrome: clinical and experimental studies.
  420. Combined oral contraceptives and the risk of cervical cancer.
  421. Commentary [on "Oral Contraceptive Pills. Prevention of Ovarian Cancer and Other Benefits"]
  422. Commitment, intimacy, and women's perceptions of premarital sex and contraceptive readiness.
  423. Common beginnings but different outcomes: the family planning programs in Pakistan and Bangladesh.
  424. The common good. The Canadian bishops and the public debate on contraception.
  425. Communication, ideation, and contraceptive behavior: evaluation of the JIGGASHA social network approach in Bangladesh. Preliminary draft.
  426. Comparative clinical evaluation of the effect on carbohydrate and lipid metabolism of two norethisterone- containing hormonal contraceptives: Mesigyna and TriNovum.
  427. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
  428. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism.
  429. Comparative study on ovarian activity, cycle stability and tolerance during administration of two low-dose oral contraceptives. [Ovarielle Aktivitat, Zyklusverhalten und Vertraglichkeit bei niedrigdosierten oralen Kontrazeptiva: Eine Vergleichsstudie.]
  430. Comparative study on the evolution of births, abortions and the use of contraceptives in a hospital in Galati. [Studiu comparativ asupra evolutiei nasterilor, avorturilor si folosirii mijloacelor contraceptive intr-un spital din Galati.]
  431. A comparative study on transportation models: Directorate of Family Planning managed transport and private carrier.
  432. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. V. Localization of higher 5alpha-reductase activity to the reproductive tract in oligozoospermic men administered supraphysiological doses of testosterone.
  433. A comparison of the clinical performance, contraceptive efficacy, reversibility and acceptability of Norplant implants and Ortho Gynae T380 intrauterine copper contraceptive device.
  434. Complications of the intrauterine device used in the Marie Stopes Family Planning Clinic, Bacau. [Complicatiile dispozitivului intrauterin folosit in Clinica de planificare familiala "Marie Stopes" Bacau.]
  435. Comprehensive family planning training evaluation in Nepal. FCA-29.
  436. Comprehensive reproductive health and family planning training curriculum. Module 14: Training of trainers.
  437. Comprehensive reproductive health and family planning training curriculum. Module 1: Introduction to family planning and the health of women and children and an overview of family planning methods.
  438. Comprehensive reproductive health and family planning training curriculum. Module 2: Infection prevention.
  439. Comprehensive reproductive health and family planning training curriculum. Module 5: Emergency contraceptive pills.
  440. Comprehensive reproductive health and family planning training curriculum. Module 7: Intrauterine devices (IUDs)
  441. Comprehensive reproductive health and family planning training curriculum. Module 8: Breastfeeding and the lactational amenorrhea method (LAM)
  442. Condom and other contraceptive use among a random sample of female adolescents: a snapshot in time.
  443. Condoms: still the most popular contraceptive.
  444. Conducting a private sector family planning country assessment. The PROFIT project: a compendium of experience and findings.
  445. Conducting regulatory assessments for commercial sector family planning. A summary.
  446. Conjugal power in rural Kenya families: its influence on women's decisions about family size and family planning practices.
  447. Conscientious and responsible demographic family planning. [Planeamento demografico familiar consciente e responsavel.]
  448. Consistency between contraceptive use and fertility in India.
  449. Consultative meeting on expanding commercial markets for oral contraceptives in developing countries, New York, 9 July 1997.
  450. Consumers' understanding of contraceptive efficacy.
  451. Contemporary hormonal contraception with Cilest as practiced by the Bulgarian Association for Family Planning. [Prilozhenieto na preparata Cilest v praktikata na Bulgarskata asotsiatsiia za semeino planirane.]
  452. Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant): a prospective study in Belgium.
  453. Contraception and family planning: social change and population control in developing countries. [Contraccezione e pianificazione familiare: trasformazioni sociali e controllo della popolazione nei paesi in via di sviluppo.]
  454. Contraception and sexually transmitted diseases.
  455. Contraception and sexually transmitted diseases.
  456. Contraception and the right of the state in the Catholic Church. [Anticoncepcion y razon de estado en la Iglesia Catolica.]
  457. The contraception conundrum: it's not just birth control anymore.
  458. Contraception during breastfeeding: a clinician's sourcebook. 2nd ed.
  459. Contraception for the adolescent patient.
  460. Contraception for women at risk: a case for the intrauterine device.
  461. Contraception in adolescents participating in a family planning program. [Anticoncepcion en adolescentes incluidas en un programa de planificacion familiar.]
  462. Contraception in adolescents. [Contraceptia la adolescente.]
  463. Contraception in diabetic women.
  464. Contraception in three Chibcha communities and the concept of natural fertility.
  465. Contraception saves health care dollars among adolescents and all women.
  466. Contraception versus abortion at request in adolescents. [Contraceptia versus avort la cerere la adolescente.]
  467. Contraception.
  468. Contraceptive advice and/or treatment to a girl under 16 years of age -- criminal liability.
  469. Contraceptive advice for teenagers in Finland.
  470. Contraceptive agents and risk of thrombosis. [Antikonzeptiva und Thromboserisiko.]
  471. Contraceptive and sexual education of adolescents. [Educatia contraceptiva si sexuala la adolescent.]
  472. Contraceptive behavior and adolescent lifestyles: a structural modeling approach.
  473. Contraceptive behavior and efficacy: the influence of illusion of fertility control and adult attachment tendencies.
  474. Contraceptive behavior of the population in the Czech Republic: results of a national survey. [Kontracepcni chovani obyvatel Ceske republiky: vysledky narodniho vyzkumu.]
  475. Contraceptive choice and reproductive health: a survey report in rural Hunan.
  476. The contraceptive choice for a Wilson's disease patient with chronic liver disease.
  477. Contraceptive choice: worldwide access to family planning. 1997 report on progress towards world population stabilization. [Wallchart]
  478. Contraceptive consultation in Africa: a practical guide to providing service. 3rd ed. [La consultation de contraception en Afrique: un guide pratique pour prestataires de service. 3rd ed.]
  479. Contraceptive consumers: gender and the political economy of birth control in the 1930s.
  480. Contraceptive decision making in a sample of Jordanian Muslim women: delineating salient beliefs.
  481. Contraceptive effectiveness and continuation in the town of Diez de Octubre. [Efectividad y continuidad de la anticoncepcion en el municipio Diez de Octubre.]
  482. Contraceptive fact sheets: a tool for logistics advisors.
  483. Contraceptive failure: levels, trends and determinants in Matlab, Bangladesh.
  484. Contraceptive knowledge, contraceptive use, and self-esteem among Navy personnel.
  485. Contraceptive methods for young adults.
  486. Contraceptive methods of adolescents. [Metode contraceptive la adolescente.]
  487. Contraceptive methods.
  488. Contraceptive methods. [Los metodos anticonceptivos.]
  489. Contraceptive methods: 2. Indications and suggestions for a choice. [Les moyens contraceptifs: 2. Indications et propositions de choix.]
  490. Contraceptive methods: potential for abuse.
  491. Contraceptive needs after age 40.
  492. Contraceptive options for adolescents.
  493. Contraceptive options for the 1990s.
  494. Contraceptive practices before and after an intervention promoting condom use to prevent HIV infection and other sexually transmitted diseases among women -- selected U.S. sites, 1993-1995.
  495. Contraceptive practices before and after an intervention promoting condom use to prevent HIV infection and other sexually transmitted diseases among women -- selected US sites, 1993-1995.
  496. Contraceptive practices of women requesting termination of pregnancy: a study from China.
  497. Contraceptive prevalence in China: findings from the 1992 National Family Planning Survey.
  498. Contraceptive quality assurance: findings of a twenty-two country survey.
  499. Contraceptive rings provide simple protection.
  500. Contraceptive self-efficacy in adolescents: a comparative study of male and female contraceptive practices.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.